Clinical Benefit of Insulin Glargine 300 U/mL Among Patients with Type 2 Diabetes Mellitus Previously Uncontrolled on Basal or Premixed Insulin in Serbia: A Prospective, Observational, Single-Arm, Multicenter, Real-World Study.

Velojic-Golubovic, Milena; Ciric, Vojislav; Dimitrijevic, Marija; Kovic, Tijana; Mitic, Milica; Olujic, Biljana; Pevac, Natasa; Radenkovic, Sasa; Radojkovic, Danijela; Vukadinovic, Selena; Popovic, Djordje S

Velojic-Golubovic, Milena; Ciric, Vojislav; Dimitrijevic, Marija; Kovic, Tijana; Mitic, Milica; Olujic, Biljana; Pevac, Natasa; Radenkovic, Sasa; Radojkovic, Danijela; Vukadinovic, Selena; Popovic, Djordje S.

Afiliação

Velojic-Golubovic M; Clinical Center Nis, Nis, Serbia.
Ciric V; Medical Faculty, University of Nis, Nis, Serbia.
Dimitrijevic M; Clinical Center Nis, Nis, Serbia.
Kovic T; Medical Faculty, University of Nis, Nis, Serbia.
Mitic M; Sanofi, Belgrade, Serbia.
Olujic B; Sanofi, Belgrade, Serbia.
Pevac N; General Hospital Cuprija, Cuprija, Serbia.
Radenkovic S; General Hospital "Dr Radivoj Simonovic", Sombor, Serbia.
Radojkovic D; General Hospital Sremska Mitrovica, Sremska Mitrovica, Serbia.
Vukadinovic S; Clinical Center Nis, Nis, Serbia.
Popovic DS; Medical Faculty, University of Nis, Nis, Serbia.

Diabetes Ther ; 12(7): 2049-2058, 2021 Jul.

Article em En | MEDLINE | ID: mdl-34160790

Palavras-chave

Basal insulin; Glargine 300 U/mL; Glycemic control; Type 2 diabetes

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Risk_factors_studies Idioma: En Revista: Diabetes Ther Ano de publicação: 2021 Tipo de documento: Article País de publicação: Estados Unidos

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google